Fatty Liver (NAFLD) and Packaged Food in India

Non-alcoholic fatty liver disease (NAFLD) — now increasingly termed metabolic dysfunction-associated steatotic liver disease (MASLD) in updated clinical nomenclature — is the accumulation of excess fat in the liver in the absence of excessive alcohol use. NAFLD exists on a spectrum: simple fatty liver (steatosis), progressing to non-alcoholic steatohepatitis (NASH/MASH) with inflammation and cell damage, and in the worst cases advancing to cirrhosis and hepatocellular carcinoma (liver cancer).

India faces a severe and growing NAFLD epidemic. A landmark 2022 meta-analysis published in the Journal of Clinical and Experimental Hepatology estimated NAFLD prevalence at 38.6% among urban Indian populations — over 180 million people with fatty liver disease. A 2024 Global Burden of Disease analysis projects that India will have the highest absolute NAFLD burden globally by 2030 if current trajectories continue.

What makes India's NAFLD epidemic particularly concerning is that it occurs at lower BMIs than in Western populations. Indian patients frequently develop NAFLD and metabolic complications at BMIs of 23–25 — within the 'normal' range by traditional standards. This 'lean NAFLD' pattern, more common in South Asians, reflects the genetic predisposition of Indian populations to visceral fat accumulation (fat around and inside abdominal organs, including the liver) even at lower total body weight. This means that weight alone is an unreliable marker of NAFLD risk for Indians.

The single most important dietary driver of NAFLD is fructose — the monosaccharide component of table sugar (sucrose) and high-fructose corn syrup (HFCS). Unlike glucose, which is metabolised by all cells in the body, fructose is primarily metabolised by the liver. When fructose intake exceeds the liver's immediate energy needs, fructose is converted to fat through de novo lipogenesis (DNL) — new fat synthesis in the liver. At high fructose intakes, DNL drives hepatic fat accumulation that is the hallmark of NAFLD.

Indian packaged foods are loaded with fructose sources. Table sugar (sucrose) is 50% fructose. High-fructose corn syrup (HFCS) — used in many packaged beverages and processed foods — contains 42–55% fructose. Every can of regular soft drink (containing 30–35g of sugar), every 200ml packaged juice tetra pack (containing 20–25g of sugar), every packaged sweet biscuit and confectionery item is delivering fructose directly to the liver.

A 2020 meta-analysis in the journal Hepatology found that a diet high in free fructose (from added sugar, not from whole fruit) was associated with significantly increased risk of developing NAFLD and NASH. Crucially, this association was independent of total caloric intake — fructose drives hepatic fat accumulation even without overall hypercaloric eating, because of its liver-specific metabolic pathway.

For an urban Indian consuming 2 packaged beverages, 2 sweet biscuit servings, and 1 packaged fruit drink daily, fructose intake from these sources alone can reach 60–80g per day — at least 3–4 times the level at which significant de novo lipogenesis occurs.

AaharIQ has identified the following categories as most impactful on fatty liver progression based on their fructose content, refined carbohydrate load, and saturated/trans fat content:

Packaged sugary beverages: Regular cola and fruit-flavoured drinks are the single most impactful category for NAFLD. Each 300ml serving delivers 30+ grams of fructose-containing sugar directly to the liver. Even 'natural' packaged fruit juices without added sugar deliver concentrated fruit fructose with none of the fibre that moderates fructose absorption from whole fruit. Packaged sweet biscuits and cookies: Combine refined maida (rapid glucose spike driving insulin resistance) with added sugar (fructose contribution) and palm oil (saturated fat). Consuming 4–6 biscuits daily contributes meaningfully to NAFLD risk in predisposed individuals. Packaged confectionery and chocolate: High sugar, high saturated fat from palm kernel oil and cocoa butter. Instant noodles: Primarily refined maida carbohydrates with high sodium. The rapid glucose spike from a large noodle serving drives postprandial insulin surges that promote hepatic fat synthesis over time. Packaged flavoured dairy desserts: Packaged kheer, gulab jamun mixes, flavoured yogurts with added sugar — combining dairy fat with significant added sugar fructose. Packaged white bread consumed in large quantities: Refined maida, moderate sugar — less concerning than the above but contributes to refined carbohydrate load.

AaharIQ's summary of the packaged food categories with the greatest impact on fatty liver progression:

For Indian patients with NAFLD (diagnosed by ultrasound or fibroscan) or those at high risk (visceral obesity, T2DM, insulin resistance, elevated ALT/AST on blood tests), AaharIQ recommends the following dietary approach in consultation with their physician or hepatologist:

Eliminate first: All packaged sugary beverages (colas, fruit drinks, packaged juices) — this single change is the highest-impact dietary intervention for NAFLD. All added sugar to the extent possible — read labels for sugar, sucrose, HFCS, fructose, glucose syrup on ingredient lists. Packaged sweet biscuits and confectionery. Packaged processed meats. Reduce significantly: White rice and maida-based packaged foods. Packaged instant noodles. Fried and deep-fried packaged snacks. Increase: Whole vegetables (fresh or minimally packaged frozen). Legumes and dal. Whole grain cereals (oats, millets, whole wheat). Fish (low-mercury varieties: rohu, pomfret, sardines, fresh water fish). Olive oil, mustard oil for cooking. Coffee without sugar. Nuts (almonds, walnuts). Monitor: Screen with ultrasound every 1–2 years if at risk. Liver function tests (ALT, AST, GGT) annually. Ask for fibroscan to assess liver stiffness if ALT is persistently elevated.